Want to see EMMA full AI Analyst Report?
EMMA Stock Chart & Stats
$0.01
<$0.01(41.41%)
At close: 4:00 PM EST
$0.01
<$0.01(41.41%)
Day’s Range― - ―
52-Week Range<$0.01 - $0.02
Previous CloseN/A
Volume11.42K
Average Volume (3M)112.45K
Market Cap
$807.16K
Enterprise Value$31.94
Total Cash (Recent Filing)$1.07M
Total Debt (Recent Filing)$31.96M
Price to Earnings (P/E)―
Beta54.88
Next Earnings
Aug 17, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.13
Shares Outstanding70,188,260
10 Day Avg. Volume152,781
30 Day Avg. Volume112,453
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-0.01
Price to Sales (P/S)0.07
P/FCF Ratio-69.38
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
High Gross MarginsSustained low-90%+ gross margins provide a durable profitability buffer versus peers. High product-level margins can support reinvestment in R&D or commercial access, improve leverage on incremental volume, and make supply/contract manufacturing economics attractive over a multi-month horizon.
Improving Operating Profitability (EBIT Positive)Transition to positive EBIT demonstrates operating leverage and cost discipline, lowering structural cash burn. Sustained operating profitability reduces near-term financing needs, strengthens the case for scaling manufacturing relationships, and indicates improving core business economics over coming quarters.
Exclusive Endari Supply AgreementAn exclusive manufacturing/supply role under a cost-plus, double-digit margin contract would structurally shift revenue toward margin-based supply income. If regulatory conditions are met, this creates a predictable revenue stream and clearer unit economics, enhancing medium-term margin sustainability.
Bears Say
Persistent Net Losses And Deep Net MarginA ~-71% net margin and ongoing losses erode retained capital and limit the company’s ability to self-fund growth. Structurally negative profitability increases reliance on external financing, raises dilution risk, and constrains strategic optionality over several quarters unless substantial revenue or cost improvements continue.
Negative Equity / Stockholders' DeficitA chronic stockholders’ deficit and material debt (~$32M) weaken balance-sheet resilience. Negative equity reduces borrowing capacity, heightens refinancing risk, and increases the probability of dilutive capital raises or restrictive covenants, impairing long-term strategic flexibility and execution.
Consistent Negative Operating And Free Cash FlowPersistent negative operating and free cash flow mean the business is not self-sustaining. Continued cash burn forces dependence on external capital for operations, raises execution risk for commercialization or supply commitments, and limits ability to invest in commercial expansion or new programs.
Emmaus Life Sciences News
EMMA FAQ
What was Emmaus Life Sciences Inc’s price range in the past 12 months?
Emmaus Life Sciences Inc lowest stock price was <$0.01 and its highest was $0.02 in the past 12 months.
What is Emmaus Life Sciences Inc’s market cap?
Emmaus Life Sciences Inc’s market cap is $807.16K.
When is Emmaus Life Sciences Inc’s upcoming earnings report date?
Emmaus Life Sciences Inc’s upcoming earnings report date is Aug 17, 2026 which is in 24 days.
How were Emmaus Life Sciences Inc’s earnings last quarter?
Emmaus Life Sciences Inc released its earnings results on May 15, 2026. The company reported -$0.05 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Emmaus Life Sciences Inc overvalued?
According to Wall Street analysts Emmaus Life Sciences Inc’s price is currently Overvalued.
Does Emmaus Life Sciences Inc pay dividends?
Emmaus Life Sciences Inc does not currently pay dividends.
What is Emmaus Life Sciences Inc’s EPS estimate?
Emmaus Life Sciences Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Emmaus Life Sciences Inc have?
Emmaus Life Sciences Inc has 70,188,260 shares outstanding.
What happened to Emmaus Life Sciences Inc’s price movement after its last earnings report?
Emmaus Life Sciences Inc reported an EPS of -$0.05 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Emmaus Life Sciences Inc?
Currently, no hedge funds are holding shares in EMMA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Emmaus Life Sciences Inc
Emmaus Life Sciences, Inc. is a commercial-stage biopharmaceutical enterprise dedicated to the discovery, development, commercialization, and sale of treatments and therapies, primarily addressing rare and orphan diseases across the United States and internationally. The company's flagship product is Endari, an L-glutamine oral powder designed to mitigate the acute complications associated with sickle cell disease in patients aged five and above, covering both pediatric and adult populations. Furthermore, Emmaus maintains a collaborative arrangement with Kainos Medicine, Inc. for the preclinical advancement of Kainos' proprietary IRAK4 inhibitor, KM10544, which is being explored as a potential anti-cancer therapeutic. Established in 2000 as Emmaus Holdings, Inc., the organization rebranded to Emmaus Life Sciences, Inc. in September 2011 and operates from its headquarters in Torrance, California.
Technical Analysis
Scinai Immunotherapeutics
―
Aditxt
―
Dermata Therapeutics
―
CERo Therapeutics Holdings
―
CDT Equity
―
Ownership Overview
―
Insiders
―
Mutual Funds
0.08% Other Institutional Investors
99.92% Public Companies and
Individual Investors